Navigation Links
Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma
Date:5/1/2009

LACHEN, Switzerland, May 1 /PRNewswire/ --

- Company Working With Authorities to Ensure Adequate Supply of Virally Inactivated Plasma Derivatives

The impending influenza pandemic will have implications for global stocks of life-saving blood and blood products, warns Swiss-based global biopharmaceutical company, Octapharma.

But it has reiterated the safety of its plasma derivatives and is working closely with health authorities and plasma suppliers to maintain the safety profile and continuous supply of its lifesaving products.

The threat to blood supplies arises as blood transfusion authorities across the globe remind blood donors to stay away if they have 'flu-like symptoms. In Germany, the Paul Ehrlich Institute, which tests blood products on behalf of the German federal health ministry, has recommended against using blood donated by people who have travelled to countries affected by the swine influenza outbreak or who have been in close contact with people who have 'flu-like symptoms or were in 'flu-affected countries in the previous 14 days.

Octapharma makes plasma derivatives used in a range of medical emergencies. The new swine H1N1 virus, with its epicentre in Mexico, does not endanger the safety of Octapharma's products. Octaplas(R), is a virally inactivated pooled plasma, which can be used in emergency situations whenever plasma transfusion is required.

Currently, Octapharma has sufficient supplies of Octaplas(R) to satisfy usual client demand. Production can be increased by up to 30 percent if demand increases. Octapharma already provides 100 per cent of plasma needs with Octaplas(R) for transfusion in Norway, Finland and Portugal.

During the manufacture of Octaplas(R), the product undergoes a solvent-detergent treatment that destroys the lipid enveloped membrane of a virus, making it inactive and unable to infect.

All influenza viruses are lipid enveloped viruses and not very resistant to inactivation. The H1N1 virus is completely inactivated by the procedures used in the manufacture of Octaplas(R) and other blood-derived biopharmaceutical products.

Notes for editors

Octapharma

The Octapharma Group is an independent, Swiss-based biopharmaceutical company operating worldwide. Octapharma's core business is the development, production, and sale of high-quality human proteins for the treatment of life-threatening diseases. The Group has more than 3,000 employees in 28 countries, and owns five modern, state-of-the-art production facilities in Austria, France, Germany, Sweden, and Mexico, respectively.

Octapharma's company mission is to provide safe and effective biopharmaceutical products derived from human blood plasma to patients in need of lifesaving therapy.

For more information about the company please visit http://www.octapharma.com/corporate/01_octapharma_news/07_news_2009/021609/oc tapharma_news_021609.html

(Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser's URL address field. Remove the space if one exists.)


'/>"/>
SOURCE Octapharma
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. PEAK Surgical Announces Completion of First PRECISE Clinical Study, Receipt of Medical Design Excellence Award for PEAK(R) Surgery System and Achievement of Over 1,000 Surgeries Using PEAK PlasmaBlade(TM)
2. Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome
3. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) Needle
4. Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
5. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) for Obstetric and Gynecologic Surgery
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes
8. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
9. Processed Tomato Products May Protect Against Inflammation, According to a Study Presented at the Experimental Biology Meeting
10. MultiCell Technologies Signs Liver Stem Cell R&D Agreement To Develop Products for the Study of Liver Cancer
11. Evidence Lacking in Multivitamin Study of Womens Risk of Cancer, Heart Disease or Death, Says Natural Products Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
(Date:6/23/2016)... and INDIANAPOLIS , June 23, ... a Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, ... winners, announced today online at www.diabetesscholars.org by ... 1 diabetes stand in the way of academic and ... the Foundation,s scholarship program since 2012, and continues to ...
(Date:6/23/2016)... , June 23, 2016 Revolutionary ... Oticon , industry leaders in advanced audiology ... of Oticon Opn ™, the world,s first internet ... possibilities for IoT devices.      (Photo: ... introduces a number of ,world firsts,: , ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
Breaking Medicine News(10 mins):